IRRAS AB (publ) (IRRAS.ST)
- Previous Close
0.1622 - Open
0.1620 - Bid 0.1603 x --
- Ask 0.1639 x --
- Day's Range
0.1561 - 0.1643 - 52 Week Range
0.1125 - 0.5980 - Volume
1,452,247 - Avg. Volume
551,316 - Market Cap (intraday)
183.785M - Beta (5Y Monthly) 1.73
- PE Ratio (TTM)
0.50 - EPS (TTM)
0.3200 - Earnings Date Feb 14, 2024 - Feb 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.15
IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. The company designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. It offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. The company also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include Hummingbird Quad ICP monitoring with drainage (H610), and Hummingbird Solo ICP monitoring (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. It markets and sells its products to hospitals through its direct sales force and a network of distribution partners. The company was incorporated in 2011 and is headquartered in Stockholm, Sweden.
www.irras.comRelated News
Compare To: IRRAS.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IRRAS.ST
Valuation Measures
Market Cap
181.75M
Enterprise Value
117.85M
Trailing P/E
0.50
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.52
Price/Book (mrq)
4.22
Enterprise Value/Revenue
2.73
Enterprise Value/EBITDA
-0.60
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-127.16%
Return on Equity (ttm)
-466.52%
Revenue (ttm)
43.1M
Net Income Avi to Common (ttm)
-196.4M
Diluted EPS (ttm)
0.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
13.1M
Total Debt/Equity (mrq)
0.23%
Levered Free Cash Flow (ttm)
-92.45M